secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-122830
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo Q3 net loss $5.1M; cash $7.8M; initiates RAINIER trial for AML
---------------------------------------------------------------------

- Net loss of $5.1M ($0.48 per share) in Q3 2024 vs $6.3M ($22.16) in Q3 2023.
- Cash and cash equivalents $7.8M as of Sept 30, 2024, down from $16.9M at Dec 31, 2023.
- Initiated Phase 1b/2 RAINIER trial for mipletamig in frontline AML based on positive dose escalation data.
- ALG.APV-527 Phase 1 data: 60% of evaluable patients (9/15) achieved stable disease as monotherapy.
- Raised $5.75M in two financings during the quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000095017024122830/0000950170-24-122830-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000095017024122830/apvo-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122830

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer